S.T. Tagawa

LBA6 Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)

S.T. Tagawa, O. Sartor, J.M. Piulats et al. · Annals of Oncology · 2025 · 21 citations · Full text

Medicine, Oncology, Pharmacology +14

Sacituzumab govitecan (IMMU-132) for patients with pretreated metastatic urothelial uancer (UC): interim results

S.T. Tagawa, Bishoy M. Faltas, Elaine T. Lam et al. · Annals of Oncology · 2017 · 20 citations · Full text

Medicine, Oncology, Urology +13

Differences in recognition of similar medication names between pharmacists and nurses: a retrospective study

Toshikazu Tsuji, Toshihiro Irisa, S.T. Tagawa et al. · Journal of Pharmaceutical Health Care and Sciences · 2015 · 14 citations · Full text

Pharmacy, Clinical Pharmacy, Pharmacy Practice +10

PSMAddition: Phase 3 Trial of [177lu]Lu-PSMA-617 Plus Standard of Care (SoC) vs. Soc Alone in Patients with Metastatic Hormone-Sensitive Prostate Cancer

H. Kim, S.T. Tagawa, Oliver Sartor et al. · International Journal of Radiation Oncology*Biology*Physics · 2024 · 14 citations

Medicine, Oncology, Urology +15

LBA9 TROPiCS-04, a randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (CT) in pretreated advanced urothelial carcinoma (aUC): Overall survival (OS) and safety analysis

P. Grivas, T.B. Powles, Christof Vulsteke et al. · Annals of Oncology · 2024 · 14 citations · Full text

Medicine, Oncology, Pharmacology +9